Cleared Traditional

BD Vacutainer Eclipse Signal Blood Collection Needle (K170824) - FDA 510(k) Clearance

Class II General Hospital device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K170824 · Becton, Dickinson and Company · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2018
Decision
518d
Days
Class 2
Risk

K170824 is an FDA 510(k) clearance for the BD Vacutainer Eclipse Signal Blood Collection Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Becton, Dickinson and Company (Franklin Lakes, US). The FDA issued a Cleared decision on August 20, 2018 after a review of 518 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind General Hospital submissions.

View all Becton, Dickinson and Company devices

Submission Details

510(k) Number K170824 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 20, 2017
Decision Date August 20, 2018
Days to Decision 518 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
389d slower than avg
Panel avg: 129d · This submission: 518d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 195
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K170824.
Immucise Intradermal Injection System
K181369 · Terumo Corporation · Nov 2018
EZ-IO Intraosseous Vascular Access System
K180395 · Arrow International, Inc. (Subsidiary of Teleflex, Inc.) · Nov 2018
Disposable Insulin Pen Needle
K181069 · Zhejiang Kindly Medical Devices Co., Ltd. · Aug 2018
EasyTouch Safety Pen Needle
K163578 · Mhc Medical Products, LLC · Aug 2018
Autokeeper
K172095 · Medexel Co.,Ltd · Jul 2018
Unifine SafeControl 5mm x 30G, Unifine SafeControl 8mm x 30G
K173881 · Owen Mumford, Ltd. · Jul 2018